drugset / Trial / NCT01613261

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

NCT01613261

NaSingle-groupOpen-labelTreatment

Summary

This is a Multicenter, Open-label, Phase 1b Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Timeline

Start
2013-08
Primary completion
2015-09
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Alisertib Small molecule Oral
Subject TAK-733 Small molecule Oral

Indications